Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with ...
Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...
Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results